A poly(propylene fumarate) - Calcium phosphate based angiogenic injectable bone cement for femoral head osteonecrosis

Chih Hung Chang, Tai Chieh Liao, Yuan Ming Hsu, Hsu Wei Fang, Chia Chun Chen, Feng Huei Lin

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Osteonecrosis of the femoral head commonly occurs when the blood supply to bone was disrupted. The general treatment for early stages of necrosis in the femoral head is core decompression. However, the long-term outcome of this operation is usually compromised due to collapse of the necrotic bone. In this study, poly(propylene fumarate) (PPF) and calcium phosphate cement (CPC) were combined to provide appropriate mechanical strength after core-decompressed femoral heads and offer the properties of osteoconductivity. Effects of different ratios of CPC to PPF on mechanical and cytotoxicity were investigated. Results show that bone cement is less cytotoxic with the C/P ratio raise, and the increment of the CPC proportion also strengthens the mechanical strength, reduces the crosslinking temperature and diminishes excessive swelling of the cement. With addition of ginsenoside Rg1 the bone cement composite can also offer angiogenic effect. The drug release profiles were analyzed and the angiogenecity of released Rg1 was confirmed by the assay of tube formation in human umbilical vein endothelial cells (HUVECs). In summary, the newly developed angiogenic bone cement composite possesses remarkable development potential for application to treating osteonecrosis of the femoral head.

Original languageEnglish
Pages (from-to)4048-4055
Number of pages8
JournalBiomaterials
Volume31
Issue number14
DOIs
Publication statusPublished - May 1 2010
Externally publishedYes

Fingerprint

Bone cement
Bone Cements
Osteonecrosis
Calcium phosphate
Thigh
Polypropylenes
Cements
Injections
Strength of materials
Bone
Bone and Bones
Fumarates
Endothelial cells
Human Umbilical Vein Endothelial Cells
Composite materials
Cytotoxicity
Decompression
Crosslinking
Propylene
Swelling

Keywords

  • Angiogenesis
  • Calcium phosphate
  • Ginsenoside Rg1
  • Injectable bone cement
  • Poly(propylene fumarate)

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

A poly(propylene fumarate) - Calcium phosphate based angiogenic injectable bone cement for femoral head osteonecrosis. / Chang, Chih Hung; Liao, Tai Chieh; Hsu, Yuan Ming; Fang, Hsu Wei; Chen, Chia Chun; Lin, Feng Huei.

In: Biomaterials, Vol. 31, No. 14, 01.05.2010, p. 4048-4055.

Research output: Contribution to journalArticle

Chang, Chih Hung ; Liao, Tai Chieh ; Hsu, Yuan Ming ; Fang, Hsu Wei ; Chen, Chia Chun ; Lin, Feng Huei. / A poly(propylene fumarate) - Calcium phosphate based angiogenic injectable bone cement for femoral head osteonecrosis. In: Biomaterials. 2010 ; Vol. 31, No. 14. pp. 4048-4055.
@article{f05a4ee2b7f7440e9ffbabf07053639b,
title = "A poly(propylene fumarate) - Calcium phosphate based angiogenic injectable bone cement for femoral head osteonecrosis",
abstract = "Osteonecrosis of the femoral head commonly occurs when the blood supply to bone was disrupted. The general treatment for early stages of necrosis in the femoral head is core decompression. However, the long-term outcome of this operation is usually compromised due to collapse of the necrotic bone. In this study, poly(propylene fumarate) (PPF) and calcium phosphate cement (CPC) were combined to provide appropriate mechanical strength after core-decompressed femoral heads and offer the properties of osteoconductivity. Effects of different ratios of CPC to PPF on mechanical and cytotoxicity were investigated. Results show that bone cement is less cytotoxic with the C/P ratio raise, and the increment of the CPC proportion also strengthens the mechanical strength, reduces the crosslinking temperature and diminishes excessive swelling of the cement. With addition of ginsenoside Rg1 the bone cement composite can also offer angiogenic effect. The drug release profiles were analyzed and the angiogenecity of released Rg1 was confirmed by the assay of tube formation in human umbilical vein endothelial cells (HUVECs). In summary, the newly developed angiogenic bone cement composite possesses remarkable development potential for application to treating osteonecrosis of the femoral head.",
keywords = "Angiogenesis, Calcium phosphate, Ginsenoside Rg1, Injectable bone cement, Poly(propylene fumarate)",
author = "Chang, {Chih Hung} and Liao, {Tai Chieh} and Hsu, {Yuan Ming} and Fang, {Hsu Wei} and Chen, {Chia Chun} and Lin, {Feng Huei}",
year = "2010",
month = "5",
day = "1",
doi = "10.1016/j.biomaterials.2010.01.124",
language = "English",
volume = "31",
pages = "4048--4055",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier Science Ltd",
number = "14",

}

TY - JOUR

T1 - A poly(propylene fumarate) - Calcium phosphate based angiogenic injectable bone cement for femoral head osteonecrosis

AU - Chang, Chih Hung

AU - Liao, Tai Chieh

AU - Hsu, Yuan Ming

AU - Fang, Hsu Wei

AU - Chen, Chia Chun

AU - Lin, Feng Huei

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Osteonecrosis of the femoral head commonly occurs when the blood supply to bone was disrupted. The general treatment for early stages of necrosis in the femoral head is core decompression. However, the long-term outcome of this operation is usually compromised due to collapse of the necrotic bone. In this study, poly(propylene fumarate) (PPF) and calcium phosphate cement (CPC) were combined to provide appropriate mechanical strength after core-decompressed femoral heads and offer the properties of osteoconductivity. Effects of different ratios of CPC to PPF on mechanical and cytotoxicity were investigated. Results show that bone cement is less cytotoxic with the C/P ratio raise, and the increment of the CPC proportion also strengthens the mechanical strength, reduces the crosslinking temperature and diminishes excessive swelling of the cement. With addition of ginsenoside Rg1 the bone cement composite can also offer angiogenic effect. The drug release profiles were analyzed and the angiogenecity of released Rg1 was confirmed by the assay of tube formation in human umbilical vein endothelial cells (HUVECs). In summary, the newly developed angiogenic bone cement composite possesses remarkable development potential for application to treating osteonecrosis of the femoral head.

AB - Osteonecrosis of the femoral head commonly occurs when the blood supply to bone was disrupted. The general treatment for early stages of necrosis in the femoral head is core decompression. However, the long-term outcome of this operation is usually compromised due to collapse of the necrotic bone. In this study, poly(propylene fumarate) (PPF) and calcium phosphate cement (CPC) were combined to provide appropriate mechanical strength after core-decompressed femoral heads and offer the properties of osteoconductivity. Effects of different ratios of CPC to PPF on mechanical and cytotoxicity were investigated. Results show that bone cement is less cytotoxic with the C/P ratio raise, and the increment of the CPC proportion also strengthens the mechanical strength, reduces the crosslinking temperature and diminishes excessive swelling of the cement. With addition of ginsenoside Rg1 the bone cement composite can also offer angiogenic effect. The drug release profiles were analyzed and the angiogenecity of released Rg1 was confirmed by the assay of tube formation in human umbilical vein endothelial cells (HUVECs). In summary, the newly developed angiogenic bone cement composite possesses remarkable development potential for application to treating osteonecrosis of the femoral head.

KW - Angiogenesis

KW - Calcium phosphate

KW - Ginsenoside Rg1

KW - Injectable bone cement

KW - Poly(propylene fumarate)

UR - http://www.scopus.com/inward/record.url?scp=77649271056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649271056&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2010.01.124

DO - 10.1016/j.biomaterials.2010.01.124

M3 - Article

C2 - 20172606

AN - SCOPUS:77649271056

VL - 31

SP - 4048

EP - 4055

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 14

ER -